Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DC-LC3in-D5 is a chemical compound that functions as an autophagy inhibitor by diminishing the process of LC3B lipidation. It forms a binding association with LC3B, disrupting the LC3B-LBP2 interaction with an IC50 of 200 nM. This compound, DC-LC3in-D5, exhibits potential for application in anti-HCV or combination cancer treatments by effectively inhibiting autophagy [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 10-14 weeks | $ 954.00 | |
50 mg | 10-14 weeks | $ 1,240.00 | |
100 mg | 10-14 weeks | $ 1,940.00 |
Description | DC-LC3in-D5 is a chemical compound that functions as an autophagy inhibitor by diminishing the process of LC3B lipidation. It forms a binding association with LC3B, disrupting the LC3B-LBP2 interaction with an IC50 of 200 nM. This compound, DC-LC3in-D5, exhibits potential for application in anti-HCV or combination cancer treatments by effectively inhibiting autophagy [1]. |
In vitro | DC-LC3in-D5 demonstrates high selectivity to LC3A/B in the proteome. DC-LC3in-D5 exhibits a potent covalent reactivity and selectivity to LC3A/B in HeLa cells [1]. Treatment of HeLa cells with DC-LC3in-D5 (3-30 μM) results in disruption of LC3B lipidation, inhibition of autophagic vesicle formation, and accumulation of p62 [1]. Western Blot Analysis [1] Cell Line: HeLa cells Concentration: 3, 10, 30 μM Incubation Time: 16 hours Result: Pre-treated accumulated significant more p62 than DMSO-treated control samples. Attenuated LC3-I/II lipidation in cells exposed to autophagy inducing conditions. |
Molecular Weight | 397.3 |
Formula | C19H22Cl2N2O3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.